Welcome to Hodoodo Chemicals

Hydroxyurea
featured

WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H540204

CAS#: 127-07-1

Description: Hydroxyurea is a fetal hemoglobin stimulator and ribonucleotide reductase inhibitor used to treat sickle cell anemia, myeloproliferative disorders, and leukemias. It decreases the production of deoxyribonucleotides and also increases levels of NO in the blood.

Chemical Structure

Hydroxyurea

CAS# 127-07-1

Instruction

Theoretical Analysis

Hodoodo Cat#: H540204
Name: Hydroxyurea
CAS#: 127-07-1
Chemical Formula: CH4N2O2
Exact Mass: 76.03
Molecular Weight: 76.050
Elemental Analysis: C, 15.79; H, 5.30; N, 36.83; O, 42.07

Price and Availability

Size	Price	Availability	Quantity
5g	USD 250	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. Hodoodo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Biosupressin; Carbamoyl oxime; Droxia; Hydroxycarbamide

IUPAC/Chemical Name: 1-hydroxyurea

InChi Key: VSNHCAURESNICA-UHFFFAOYSA-N

InChi Code: InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

SMILES Code: O=C(N)NO

Appearance: Solid powder

Purity: >97% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 76.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749-58. doi: 10.1517/14740338.2015.1088827. Epub 2015 Sep 14. Review. PubMed PMID: 26366626.

2: Lederman HM, Connolly MA, Kalpatthi R, Ware RE, Wang WC, Luchtman-Jones L, Waclawiw M, Goldsmith JC, Swift A, Casella JF; BABY HUG Investigators. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics. 2014 Oct;134(4):686-95. doi: 10.1542/peds.2014-0571. Epub 2014 Sep 1. PubMed PMID: 25180279; PubMed Central PMCID: PMC4179098.

3: Samuelson B, Chai-Adisaksopha C, Garcia D. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. J Thromb Thrombolysis. 2015 Nov;40(4):474-9. doi: 10.1007/s11239-015-1218-2. Review. PubMed PMID: 25894476.

4: Fraser DI, Liu KT, Reid BJ, Hawkins E, Sevier A, Pyle M, Robinson JW, Ouellette PH, Ballantyne JS. Widespread Natural Occurrence of Hydroxyurea in Animals. PLoS One. 2015 Nov 24;10(11):e0142890. doi: 10.1371/journal.pone.0142890. eCollection 2015. PubMed PMID: 26600157; PubMed Central PMCID: PMC4658187.

5: Sheehan VA, Crosby JR, Sabo A, Mortier NA, Howard TA, Muzny DM, Dugan-Perez S, Aygun B, Nottage KA, Boerwinkle E, Gibbs RA, Ware RE, Flanagan JM. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia. PLoS One. 2014 Oct 31;9(10):e110740. doi: 10.1371/journal.pone.0110740. eCollection 2014. PubMed PMID: 25360671; PubMed Central PMCID: PMC4215999.

6: Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol. 2016 Feb;91(2):238-42. doi: 10.1002/ajh.24255. PubMed PMID: 26615793.

7: Wiczling P, Liem RI, Panepinto JA, Garg U, Abdel-Rahman SM, Kearns GL, Neville KA. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. J Clin Pharmacol. 2014 Sep;54(9):1016-22. doi: 10.1002/jcph.303. Epub 2014 Apr 11. PubMed PMID: 24729271.

8: Internullo M, Giannelli V, Sardo L, Antonaglia C, Villani T, Angelici E, Palange P. Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature. Eur Rev Med Pharmacol Sci. 2014;18(2):190-3. PubMed PMID: 24488907.

9: Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics. 2013 Oct;132(4):677-83. doi: 10.1542/peds.2013-0333. Epub 2013 Sep 2. PubMed PMID: 23999955; PubMed Central PMCID: PMC4074648.

10: Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol. 2013 Feb;88(2):116-9. doi: 10.1002/ajh.23365. Epub 2012 Dec 17. PubMed PMID: 23255310; PubMed Central PMCID: PMC4673980.

11: Summarell CC, Sheehan VA. Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. Exp Biol Med (Maywood). 2016 Apr;241(7):737-44. doi: 10.1177/1535370216639737. Epub 2016 Mar 17. PubMed PMID: 26993671; PubMed Central PMCID: PMC4950384.

12: Dong M, McGann PT, Mizuno T, Ware RE, Vinks AA. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol. 2016 Apr;81(4):742-52. doi: 10.1111/bcp.12851. Epub 2016 Feb 5. PubMed PMID: 26615061; PubMed Central PMCID: PMC4799926.

13: Imai H, Matsumura N, Yamazaki Y, Kanayama Y, Masuda T, Kuwako T, Kamide Y, Tomizawa T, Matsumoto S, Mitsui T, Kaira K, Ono A, Koga Y, Shibusawa N, Sunaga N, Hisada T, Yokoo H, Yamada M. Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case. Intern Med. 2015;54(24):3171-6. doi: 10.2169/internalmedicine.54.5069. Epub 2015 Dec 15. PubMed PMID: 26666606.

14: Banan M. Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? Ann Hematol. 2013 Mar;92(3):289-99. doi: 10.1007/s00277-012-1671-3. Epub 2013 Jan 15. Review. PubMed PMID: 23318979.

15: Strouse JJ. Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease? Pediatr Blood Cancer. 2015 Jun;62(6):929-30. doi: 10.1002/pbc.25471. Epub 2015 Mar 8. PubMed PMID: 25755219; PubMed Central PMCID: PMC4405448.

16: Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011 Nov 3;118(18):4985-91. doi: 10.1182/blood-2011-07-364190. Epub 2011 Aug 29. PubMed PMID: 21876119; PubMed Central PMCID: PMC3208303.

17: Butler D, Nambudiri VE, Nandi T. Hydroxyurea-associated acral erythema in a patient with polycythemia vera. Am J Hematol. 2014 Sep;89(9):931-2. doi: 10.1002/ajh.23698. Epub 2014 Apr 15. PubMed PMID: 24585573.

18: Estepp JH, Melloni C, Thornburg CD, Wiczling P, Rogers Z, Rothman JA, Green NS, Liem R, Brandow AM, Crary SE, Howard TH, Morris MH, Lewandowski A, Garg U, Jusko WJ, Neville KA; Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. J Clin Pharmacol. 2016 Mar;56(3):298-306. doi: 10.1002/jcph.598. Epub 2015 Oct 15. PubMed PMID: 26201504; PubMed Central PMCID: PMC4892120.

19: Staake MD, Kashinatham A, McMorris TC, Estes LA, Kelner MJ. Hydroxyurea derivatives of irofulven with improved antitumor efficacy. Bioorg Med Chem Lett. 2016 Apr 1;26(7):1836-8. doi: 10.1016/j.bmcl.2016.02.028. Epub 2016 Feb 13. PubMed PMID: 26922141.

20: Iman M, Khansefid Z, Davood A. Modeling and Proposed Molecular Mechanism of Hydroxyurea Through Docking and Molecular Dynamic Simulation to Curtail the Action of Ribonucleotide Reductase. Recent Pat Anticancer Drug Discov. 2016;11(4):461-468. PubMed PMID: 27670694.

Your view history

Hydroxyurea featured